Hims & Hers Health (HIMS) Scheduled to Post Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is scheduled to be posting its quarterly earnings results after the market closes on Monday, November 4th. Analysts expect Hims & Hers Health to post earnings of $0.06 per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business’s revenue was up 51.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.03) earnings per share. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Hims & Hers Health Trading Up 8.2 %

Shares of Hims & Hers Health stock opened at $20.37 on Friday. The stock has a market capitalization of $4.38 billion, a price-to-earnings ratio of 254.66 and a beta of 1.06. Hims & Hers Health has a twelve month low of $5.97 and a twelve month high of $25.74. The business’s 50 day simple moving average is $18.01 and its 200-day simple moving average is $18.06.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of recent research reports. Truist Financial raised their target price on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Bank of America lifted their price objective on shares of Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Needham & Company LLC began coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price for the company. Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.21.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 269,739 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the completion of the transaction, the chief financial officer now owns 145,763 shares of the company’s stock, valued at $2,960,446.53. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Hims & Hers Health news, CFO Oluyemi Okupe sold 269,739 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $20.31, for a total value of $5,478,399.09. Following the transaction, the chief financial officer now owns 145,763 shares in the company, valued at approximately $2,960,446.53. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $23.16, for a total value of $54,171.24. Following the completion of the transaction, the insider now owns 169,935 shares in the company, valued at $3,935,694.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 858,665 shares of company stock valued at $15,148,890. Corporate insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.